Armata Pharmaceuticals Announces 3rd Quarter 2022 Results and Provides Corporate Update.

MARINA DEL REY, Calif: Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its third quarter 2022 and provided a corporate update.

Third Quarter 2022 and Recent Developments:

SWARM-P.a. enrolling final Phase 2 MAD cohort evaluating AP-PA02 in cystic fibrosis

AP-PA02 Phase 2 non-cystic fibrosis bronchiectasis (NCFB) study progressing toward site activation and first patient dosed

AP-SA02 bacteremia study progressing through Phase 1b cohort

AP-SA02 prosthetic joint infection study advancing through start-up activities

"During the third quarter, we have made significant progress in the SWARM-P.a. study. We now anticipate enrolling the last subject in the fourth quarter with top-line data expected in early 2023," stated Dr. Brian Varnum, Chief Executive Officer of Armata. "Concurrently, we made progress with our second lead program, AP-SA02 in Staphylococcus aureus bacteremia, enrolling in the Phase 1b portion of the diSArm study while continuing to expand the study reach in the United States and abroad. Importantly, we achieved regulatory approvals required to activate clinical sites in Australia, which we believe may accelerate enrollment in this difficult-to-treat patient population. Finally, our pipeline expansion activities continue to progress, with ongoing site activation for the Tailwind study evaluating AP-PA02 in non-cystic fibrosis bronchiectasis, and study start-up activities for AP-SA02 in prosthetic joint infections."

Third Quarter 2022 Financial Results

Grant Revenue. The Company recognized grant revenue of approximately $1.3 million for the three months ended September 30, 2022, which represents Medical Technology Enterprise Consortium...